Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Oct;36(10):2342–2345. doi: 10.1128/aac.36.10.2342

Bactericidal activity of ramoplanin against antibiotic-resistant enterococci.

C C Johnson 1, S Taylor 1, P Pitsakis 1, P May 1, M E Levison 1
PMCID: PMC245501  PMID: 1444316

Abstract

Ramoplanin, a new lipoglycodepsipeptide antibiotic, was uniformly active against 65 strains of enterococci, including strains highly resistant to vancomycin, penicillin G, and gentamicin. MBCs were usually within a fourfold dilution of the MICs. In time-kill studies, ramoplanin alone demonstrated dose-dependent bactericidal activity against enterococcal strains that resisted killing by vancomycin or penicillin in combination with gentamicin.

Full text

PDF
2343

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartoloni A., Colao M. G., Orsi A., Dei R., Giganti E., Parenti F. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile. J Antimicrob Chemother. 1990 Nov;26(5):627–633. doi: 10.1093/jac/26.5.627. [DOI] [PubMed] [Google Scholar]
  2. Biavasco F., Manso E., Varaldo P. E. In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile. Antimicrob Agents Chemother. 1991 Jan;35(1):195–197. doi: 10.1128/aac.35.1.195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bush L. M., Calmon J., Cherney C. L., Wendeler M., Pitsakis P., Poupard J., Levison M. E., Johnson C. C. High-level penicillin resistance among isolates of enterococci. Implications for treatment of enterococcal infections. Ann Intern Med. 1989 Apr 1;110(7):515–520. doi: 10.7326/0003-4819-110-7-515. [DOI] [PubMed] [Google Scholar]
  4. Courvalin P. Resistance of enterococci to glycopeptides. Antimicrob Agents Chemother. 1990 Dec;34(12):2291–2296. doi: 10.1128/aac.34.12.2291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Herman D. J., Gerding D. N. Screening and treatment of infections caused by resistant enterococci. Antimicrob Agents Chemother. 1991 Feb;35(2):215–219. doi: 10.1128/aac.35.2.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Jones R. N., Barry A. L. In vitro evaluation of ramoplanin (A16686 or MDL62198). A new depsipeptide complex for potential topical use. Diagn Microbiol Infect Dis. 1989 May-Jun;12(3):279–282. doi: 10.1016/0732-8893(89)90029-1. [DOI] [PubMed] [Google Scholar]
  7. Kaplan A. H., Gilligan P. H., Facklam R. R. Recovery of resistant enterococci during vancomycin prophylaxis. J Clin Microbiol. 1988 Jun;26(6):1216–1218. doi: 10.1128/jcm.26.6.1216-1218.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kaye D. Enterococci. Biologic and epidemiologic characteristics and in vitro susceptibility. Arch Intern Med. 1982 Oct 25;142(11):2006–2009. doi: 10.1001/archinte.142.11.2006. [DOI] [PubMed] [Google Scholar]
  9. Leclercq R., Derlot E., Duval J., Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med. 1988 Jul 21;319(3):157–161. doi: 10.1056/NEJM198807213190307. [DOI] [PubMed] [Google Scholar]
  10. Maki D. G., Agger W. A. Enterococcal bacteremia: clinical features, the risk of endocarditis, and management. Medicine (Baltimore) 1988 Jul;67(4):248–269. [PubMed] [Google Scholar]
  11. Maple P. A., Hamilton-Miller J. M., Brumfitt W. Comparative in-vitro activity of vancomycin, teicoplanin, ramoplanin (formerly A16686), paldimycin, DuP 721 and DuP 105 against methicillin and gentamicin resistant Staphylococcus aureus. J Antimicrob Chemother. 1989 Apr;23(4):517–525. doi: 10.1093/jac/23.4.517. [DOI] [PubMed] [Google Scholar]
  12. Murray B. E. The life and times of the Enterococcus. Clin Microbiol Rev. 1990 Jan;3(1):46–65. doi: 10.1128/cmr.3.1.46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. O'Hare M. D., Ghosh G., Felmingham D., Grüneberg R. N. In-vitro studies with ramoplanin (MDL 62,198): a novel lipoglycopeptide antimicrobial. J Antimicrob Chemother. 1990 Feb;25(2):217–220. doi: 10.1093/jac/25.2.217. [DOI] [PubMed] [Google Scholar]
  14. Pearson R. D., Steigbigel R. T., Davis H. T., Chapman S. W. Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother. 1980 Nov;18(5):699–708. doi: 10.1128/aac.18.5.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rhinehart E., Smith N. E., Wennersten C., Gorss E., Freeman J., Eliopoulos G. M., Moellering R. C., Jr, Goldmann D. A. Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N Engl J Med. 1990 Dec 27;323(26):1814–1818. doi: 10.1056/NEJM199012273232606. [DOI] [PubMed] [Google Scholar]
  16. Shlaes D. M., Bouvet A., Devine C., Shlaes J. H., al-Obeid S., Williamson R. Inducible, transferable resistance to vancomycin in Enterococcus faecalis A256. Antimicrob Agents Chemother. 1989 Feb;33(2):198–203. doi: 10.1128/aac.33.2.198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Somner E. A., Reynolds P. E. Inhibition of peptidoglycan biosynthesis by ramoplanin. Antimicrob Agents Chemother. 1990 Mar;34(3):413–419. doi: 10.1128/aac.34.3.413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Tritz D. M., Iwen P. C., Woods G. L. Evaluation of MicroScan for identification of Enterococcus species. J Clin Microbiol. 1990 Jun;28(6):1477–1478. doi: 10.1128/jcm.28.6.1477-1478.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Yamane N., Jones R. N. In vitro activity of 43 antimicrobial agents tested against ampicillin-resistant enterococci and gram-positive species resistant to vancomycin. Diagn Microbiol Infect Dis. 1991 Jul-Aug;14(4):337–345. doi: 10.1016/0732-8893(91)90025-b. [DOI] [PubMed] [Google Scholar]
  20. Zervos M. J., Dembinski S., Mikesell T., Schaberg D. R. High-level resistance to gentamicin in Streptococcus faecalis: risk factors and evidence for exogenous acquisition of infection. J Infect Dis. 1986 Jun;153(6):1075–1083. doi: 10.1093/infdis/153.6.1075. [DOI] [PubMed] [Google Scholar]
  21. Zervos M. J., Kauffman C. A., Therasse P. M., Bergman A. G., Mikesell T. S., Schaberg D. R. Nosocomial infection by gentamicin-resistant Streptococcus faecalis. An epidemiologic study. Ann Intern Med. 1987 May;106(5):687–691. doi: 10.7326/0003-4819-106-5-687. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES